The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases

Yuya Fujita, Manabu Kinoshita, Tomohiko Ozaki, Koji Takano, Kei Kunimasa, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Toru Kumagai, Haruhiko Kishima, Fumio ImamuraNeuro-Oncology 2020 · DOI

TL;DR

This study reveals that non-small-cell lung cancer (NSCLC) patients with EGFR mutations and a single brain metastasis (BM) have a significantly better prognosis compared to those without EGFR mutations. The findings underscore the importance of localized treatment strategies for these patients, suggesting that targeted therapies combined with local interventions can improve survival outcomes.

What Problem Does This Paper Address?

Brain metastases (BMs) are a significant cause of mortality in non-small-cell lung cancer (NSCLC) patients, historically associated with a poor prognosis and treated primarily with palliative care like steroids and whole-brain radiation therapy (WBRT). The advent of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized treatment for EGFR-mutated NSCLC (EGFR-mt NSCLC), improving progression-free and overall survival. However, the specific impact of EGFR mutation status and the number of brain metastases on survival, particularly in the context of emerging local treatment options like stereotactic radiosurgery (SRS), remained an area requiring deeper investigation. This paper aims to clarify the prognostic significance of EGFR mutation status and the number of BMs, and to identify optimal management strategies for NSCLC patients with BMs.

Methods

This was a retrospective observational study that analyzed data from 647 NSCLC patients diagnosed between January 2008 and December 2015. The study focused on 266 patients who developed brain metastases. Key data points collected included EGFR mutation status, overall survival (OS) from diagnosis, OS after BM diagnosis, and the time from initial diagnosis to BM development. Statistical analyses included Fisher's exact test for categorical variables, Kaplan-Meier method with log-rank test for survival analysis, and Cox proportional hazards models to identify risk factors for BM development and prognostic factors for survival.

Datasets

The study utilized a retrospective dataset of 647 NSCLC patients from the Osaka International Cancer Institute. This dataset included information on patient demographics, EGFR mutation status, stage at diagnosis, ECOG performance status, number of brain metastases, tissue type, and treatment modalities for BMs. No new benchmarks were introduced; the study relied on existing patient data.

Key Insights and Ideas

  • EGFR Mutation as a Favorable Prognostic Indicator for Single BM: The most striking finding is that EGFR-mutated NSCLC patients with a single brain metastasis exhibit significantly better survival outcomes compared to their EGFR wild-type counterparts. This suggests a distinct biological behavior or response to treatment in this specific subgroup.
  • Oligometastasis is Primarily an EGFR-mt Phenomenon: The study posits that the "oligometastatic state" (a state of limited metastatic spread) is predominantly observed in EGFR-mt NSCLC patients. This implies that EGFR mutations might influence the pattern and extent of metastatic disease.
  • Timely BM Development: Brain metastases tend to develop within the initial 2-3 years following the diagnosis of NSCLC, regardless of EGFR mutation status, though EGFR-mt patients may develop them more rapidly.
  • Local Therapies are Crucial: Effective local therapies, such as surgical resection and SRS, are strongly associated with improved survival after the development of BMs. This reinforces the importance of aggressive local management for limited metastatic disease.

Key Results

  • Out of 647 NSCLC patients, 252 (38.8%) had EGFR mutations.
  • EGFR-mt patients showed a higher rate and frequency of developing BMs compared to EGFR-wt patients.
  • EGFR-mt patients had a significantly longer median overall survival (22 months) compared to EGFR-wt patients (11 months) after BM diagnosis (P = .012).
  • Univariate and multivariate analyses identified good performance status, presence of EGFR-mt, single BM, and receiving local therapies as significantly associated with favorable prognosis after BM diagnosis.
  • For EGFR-mt patients, a single metastasis was associated with significantly longer survival after BMs (P = .0009), a benefit not observed in EGFR-wt patients.
  • Local therapies (SRS, operation) were significantly associated with prolonged survival after developing BMs (HR 0.51, P = .0002).

Limitations and Future Work

The authors acknowledge several limitations:

  • Cohort Specificity: The study cohort primarily consisted of Japanese nationals, which may limit generalizability due to potential racial differences in NSCLC presentation and treatment response.
  • Underrepresentation of BMs: The screening guidelines for BMs (based on primary tumor size) might have led to an underrepresentation of BMs in patients with smaller primary tumors.
  • Selection Bias: The retrospective nature and selection of patients from a single institution could introduce bias in treatment choices.

Future work should focus on prospective studies to confirm these findings and address the limitations. Further research into the underlying biological mechanisms driving the improved prognosis in EGFR-mt patients with single BMs and the optimal sequencing of EGFR-TKIs with local therapies is also warranted.

Summary updated

Abstract

Single BM with EGFR-mt performed better than other groups. Furthermore, effective local therapies were recommended to achieve better outcomes.
BibTeX
@inproceedings{fujita2020impact,
  author = {Yuya Fujita and Manabu Kinoshita and Tomohiko Ozaki and Koji Takano and Kei Kunimasa and Madoka Kimura and Takako Inoue and Motohiro Tamiya and Kazumi Nishino and Toru Kumagai and Haruhiko Kishima and Fumio Imamura},
  title = {{The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases}},
  booktitle = {Neuro-Oncology},
  year = {2020},
  doi = {10.1093/noajnl/vdaa064},
}
Figure